Pharmacotherapeutics for Advanced Practice Nurse Prescribers 4th Edition Woo Robinson Test Bank – Complete Practice & Review

PHARMACOTHERAPEUTICS FOR ADVANCED M M


Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 4t
PRACTICE NURSE PRESCRIBERS,
M
h
M

4th EDITION W
M
M M M

M
M

M
M

M




OO edition
ROBINSON MTESTBANK
Woo Robinson Test BankM M M M M



PharmacotherapeuticsMforMAdvancedMPracticeMNurseMPrescribers,M4thMeditionMWooMRobinsonMTestMBank

ChapterM1.MTheMRoleMofMtheMNurseMPractitionerMasMPrescrib

erMMultipleMChoice
IdentifyMtheMchoiceMthatMbestMcompletesMtheMstatementMorManswersMtheMquestion.

M 1.MNurseMpractitionerMprescriptiveMauthorityMisMregulatedM by:
1. TheMNationalMCouncilMofMStateMBoardsMofMNursing
2. TheMU.S.MDrugMEnforcementMAdministration
3. TheMStateMBoardMofMNursingMforMeachMstate
4. TheMStateMBoardMofMPharmacy

M2.MTheMbenefitsMtoMtheMpatientMofMhavingManMAdvancedMPracticeMRegisteredMNurseM(APRN)Mpresc
riberMinclude:
1. NursesMknowMmoreMaboutMPharmacologyMthanMotherMprescribersMbecauseMtheyMtak
eMitMbothMinMtheirMbasicMnursingMprogramMandMinMtheirMAPRNMprogram.
2. NursesMcareMforMtheMpatientMfromMaMholisticMapproachMandMincludeMtheMpatien
tMinMdecisionMmakingMregardingMtheirMcare.
3. APRNsMareMlessMlikelyMtoMprescribeMnarcoticsMandMotherMcontrolledMsubstances.
4. APRNsMareMableMtoMprescribeMindependentlyMinMallMstates,MwhereasMaMphysicia
n’sMassistantMneedsMtoMhaveMaMphysicianMsupervisingMtheirMpractice.
M 3.MClinicalMjudgmentMinMprescribingMincludes:
1. FactoringMinMtheMcostMtoMtheMpatientMofMtheMmedicationMprescribed
2. AlwaysMprescribingMtheMnewestMmedicationMavailableMforMtheMdiseaseMprocess
3. HandingMoutMdrugMsamplesMtoMpoorMpatients
4. PrescribingMallMgenericMmedicationsMtoMcutMcosts
M 4.MCriteriaMforMchoosingManMeffectiveMdrugMforMaMdisorderM include:
1. AskingMtheMpatientMwhatMdrugMtheyMthinkMwouldMworkMbestMforMthem
2. ConsultingMnationallyMrecognizedMguidelinesMforMdiseaseMmanagement
3. PrescribingMmedicationsMthatMareMavailableMasMsamplesMbeforeMwritingMaMprescription
4. FollowingMU.S.MDrugMEnforcementMAdministrationMguidelinesMforMprescribing
M 5.MNurseMpractitionerMpracticeMmayMthriveMunderMhealth-careMreformMbecauseMof:
1. TheMdemonstratedMabilityMofMnurseMpractitionersMtoMcontrolMcostsMandMimproveMpati
entMoutcomes
2. TheMfactMthatMnurseMpractitionersMwillMbeMableMtoMpracticeMindependently
3. TheMfactMthatMnurseMpractitionersMwillMhaveMfullMreimbursementMunderMheal
th-McareMreform
4. TheMabilityMtoMshiftMaccountabilityMforMMedicaidMtoMtheMstateMlevel

, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 4th
M M M M M M



edition Woo Robinson Test Bank
M M M M M




ChapterM1.MTheMRoleMofMtheMNurseMPractitionerMasMPrescrib
erMAnswerMSection

MULTIPLEMCHOICE

1.MANS: 3 PTS: 1
2.MANS: 2 PTS: 1
3.MANS: 1 PTS: 1
4.MANS: 2 PTS: 1
5.MANS: 1 PTS: 1

, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 4th
M M M M M M



edition Woo Robinson Test Bank
M M M M M




ChapterM2.MReviewMofMtheMBasicMPrinciplesMofMPharmacolog

yMMultipleMChoice
IdentifyMtheMchoiceMthatMbestMcompletesMtheMstatementMorManswersMtheMquestion.


M1.MAMpatient’sMnutritionalMintakeMandMlaboratoryMresultsMreflectMhypoalbuminemia.MThisMisMcritic
alMtoMprescribingMbecause:
1. DistributionMofMdrugsMtoMtargetMtissueMmayMbeMaffected.
2. TheMsolubilityMofMtheMdrugMwillMnotMmatchMtheMsiteMofMabsorption.
3. ThereMwillMbeMlessMfreeMdrugMavailableMtoMgenerateManMeffect.
4. DrugsMboundMtoMalbuminMareMreadilyMexcretedMbyMtheMkidneys.
M 2.MDrugsMthatMhaveMaMsignificantMfirst-passM effect:
1. MustMbeMgivenMbyMtheMenteralM(oral)MrouteMonly
2. BypassMtheMhepaticMcirculation
3. AreMrapidlyMmetabolizedMbyMtheMliverMandMmayMhaveMlittleMifManyMdesiredMaction
4. AreMconvertedMbyMtheMliverMtoMmoreMactiveMandMfat-solubleMforms
M 3.MTheMrouteMofMexcretionMofMaMvolatileMdrugMwillMlikelyMbeM the:
1. Kidneys
2. Lungs
3. BileMandMfeces
4. Skin

M4.MMedroxyprogesteroneM(DepoMProvera)MisMprescribedMintramuscularlyM(IM)MtoMcreateMaMstor
ageMreservoirMofMtheMdrug.MStorageMreservoirs:
1. AssureMthatMtheMdrugMwillMreachMitsMintendedMtargetMtissue
2. AreMtheMreasonMforMgivingMloadingMdoses
3. IncreaseMtheMlengthMofMtimeMaMdrugMisMavailableMandMactive
4. AreMmostMcommonMinMcollagenMtissues
M 5.MTheMNPMchoosesMtoMgiveMcephalexinMeveryM8MhoursMbasedMonMknowledgeMofMtheMdrug’s:
1. PropensityMtoMgoMtoMtheMtargetMreceptor
2. BiologicalMhalf-life
3. Pharmacodynamics
4. SafetyMandMsideMeffects

M6.MAzithromycinMdosingMrequiresMthatMtheMfirstMday’sMdosageMbeMtwiceMthoseMofMtheMotherM4MdaysM
ofMtheMprescription.MThisMisMconsideredMaMloadingMdose.MAMloadingMdose:
1. RapidlyMachievesMdrugMlevelsMinMtheMtherapeuticMrange
2. RequiresMfour-MtoMfive-half-livesMtoMattain
3. IsMinfluencedMbyMrenalMfunction
4. IsMdirectlyMrelatedMtoMtheMdrugMcirculatingMtoMtheMtargetMtissues

M7.MTheMpointMinMtimeMonMtheMdrugMconcentrationMcurveMthatMindicatesMtheMfirstMsignMofMaMtherapeuticM
effectMisMthe:
1. MinimumMadverseMeffectMlevel
2. PeakMofMaction

, Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 4th
M M M M M M



edition Woo Robinson Test Bank
M M M M M




3. OnsetMofMaction
4. TherapeuticMrange

M 8.MPhenytoinMrequiresMthatMaMtroughMlevelMbeMdrawn.MPeakMandMtroughMlevelsMareMdone:
1. WhenMtheMdrugMhasMaMwideMtherapeuticMrange
2. WhenMtheMdrugMwillMbeMadministeredMforMaMshortMtimeMonly
3. WhenMthereMisMaMhighMcorrelationMbetweenMtheMdoseMandMsaturationMofMreceptorMsites
4. ToMdetermineMifMaMdrugMisMinMtheMtherapeuticMrange

M 9.MAMlaboratoryMresultMindicatesMthatMtheMpeakMlevelMforMaMdrugMisMaboveMtheMminimumM toxicMconcentration.
ThisMmeansMthatMthe:
1. ConcentrationMwillMproduceMtherapeuticMeffects
2. ConcentrationMwillMproduceManMadverseMresponse
3. TimeMbetweenMdosesMmustMbeMshortened
4. DurationMofMactionMofMtheMdrugMisMtooMlong
10.MDrugsMthatMareMreceptorMagonistsMmayMdemonstrateMwhatMproperty?
1. IrreversibleMbindingMtoMtheMdrugMreceptorMsite
2. UpregulationMwithMchronicMuse
3. DesensitizationMorMdownregulationMwithMcontinuousMuse
4. InverseMrelationshipMbetweenMdrugMconcentrationMandMdrugMaction
11.MDrugsMthatMareMreceptorMantagonists,MsuchMasMbetaMblockers,MmayMcause:
1. DownregulationMofMtheMdrugMreceptor
2. AnMexaggeratedMresponseMifMabruptlyMdiscontinued
3. PartialMblockadeMofMtheMeffectsMofMagonistMdrugs
4. AnMexaggeratedMresponseMtoMcompetitiveMdrugMagonists
12.MFactorsMthatMaffectMgastricMdrugMabsorptionMinclude:
1. LiverMenzymeMactivity
2. Protein-bindingMpropertiesMofMtheMdrugMmolecule
3. LipidMsolubilityMofMtheMdrug
4. AbilityMtoMchewMandMswallow

13.MDrugsMadministeredMviaM IV:
1. NeedMtoMbeMlipidMsolubleMinMorderMtoMbeMeasilyMabsorbed
2. BeginMdistributionMintoMtheMbodyMimmediately
3. AreMeasilyMabsorbedMifMtheyMareMnonionized
4. MayMuseMpinocytosisMtoMbeMabsorbed
14.MWhenMaMmedicationMisMaddedMtoMaMregimenMforMaMsynergisticMeffect,MtheMcombinedMeffectMofMtheMdrugsMis:
1. TheMsumMofMtheMeffectsMofMeachMdrugMindividually
2. GreaterMthanMtheMsumMofMtheMeffectsMofMeachMdrugMindividually
3. LessMthanMtheMeffectMofMeachMdrugMindividually
4. NotMpredictable,MasMitMvariesMwithMeachMindividual
15.MWhichMofMtheMfollowingMstatementsMaboutMbioavailabilityMisMtrue?
1. BioavailabilityMissuesMareMespeciallyMimportantMforMdrugsMwithMnarrowMtherapeu
ticMrangesMorMsustained-releaseMmechanisms.
2. AllMbrandsMofMaMdrugMhaveMtheMsameMbioavailability.